Approximately 1 in 6 people will suffer major depression at one point in their lives, and while there are various antidepressants on the market, many patients remain severely under-treated.
“We know that treatment of depression and anxiety makes good sense for health and wellbeing... it makes sound economic sense too”
Current first-line therapies take between 3 and 12 weeks to work, and it is often during this long lag-time that the most debilitating symptoms of depression occur. Around 40% of patients remain clinically ill after a year of treatment, highlighting the urgent need for alternative therapies.
We have identified an innovative solution to bridge this gap by developing a rapid-acting antidepressant.
Our solution, SPL801B, builds on research published in Nature by Zanos et al 2016.
SPL801B is based on an active metabolite of ketamine, which we are developing as a rapid-acting antidepressant. SPL801B has a different mode of action to ketamine, has a promising safety profile and early studies indicate a lack of dissociative and addictive side effects.